Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Steven Madden heads into its November 4 earnings date with the Street leaning bullish, insiders selling, and options traders more optimistic than usual.
The clearest tension is between the analyst community and the people running the company. The consensus is a buy, the mean price target is $52.40 against a current price of $45.58, implying roughly 15% upside. BMO Capital initiated coverage in September with an Outperform rating and a $60 target, the most bullish call on the Street. Piper Sandler lifted its target to $55 in August. The direction of travel has been uniformly upward following the July 30 Q2 print, when multiple firms raised targets after results came in well above prior estimates.
Yet insiders used that post-earnings strength to sell. The President, Amelia Varela, disposed of 15,000 shares at around $48.59 on August 5, worth approximately $729,000. Directors sold on the same day and the preceding day, also at prices near $48 to $49. None of the trades appear to be under pre-arranged 10b5-1 plans. Net insider activity over the trailing 90 days amounts to roughly 49,000 shares sold for a combined value of about $2.3 million. There was no corresponding buying. That cluster of discretionary sales near post-earnings highs is the one data point that cuts against the analyst optimism.
Options positioning adds a further nuance. The put/call ratio has dropped sharply, to 0.17, well below its 20-day average of 0.20 and more than one standard deviation below that mean. That reflects unusually heavy call positioning relative to puts: a more bullish skew than normal rather than the defensive hedging more typical ahead of an earnings catalyst. The 52-week high for the PCR is 1.54, so the current reading represents near maximum call dominance over the past year, sitting just above the 52-week low of 0.08.
The borrow market is consistent with a low-conviction short setup. Availability is exceptionally loose at roughly 8,550%, meaning shares to borrow vastly outnumber those already lent out. Short interest is just under 5% of the free float, and borrowing costs are low at 0.41%, though costs have edged up about 11% over the past week. The short score, at 38.7, ranks in the 41st percentile of the universe, not a name where bears are particularly active or pressed. An availability spike to the 20% utilization level briefly appeared in mid-September but quickly resolved; the borrow market has since loosened materially.
The bull case rests on three pillars: fashion tailwinds toward dressier footwear lifting full-price sell-through, EBIT margin recovery from a roughly 7% trough (down more than 400 basis points last year), and Kurt Geiger adding a premium revenue stream with pro forma Q1 growth of 23%. The bear case is more concentrated: tariff pressure, cautious wholesale partners pulling back on orders, and the risk that EPS falls as low as $1.75 next year if the company cannot fully offset those headwinds. UBS sits at Neutral with a $45 target, essentially flat to the current price, the only prominent skeptic in a group otherwise skewed toward buy ratings. The EV/EBITDA multiple is around 12.7 times, easing slightly over the past 30 days, while the PE ratio sits near 17.2 times. EPS momentum ranks in the 80th percentile on a 90-day basis, and analyst recommendation divergence ranks in the 98th percentile, the latter reflecting how unusually one-sided the bullish consensus has become.
Peers were broadly stronger on the week. DECK gained 5.1%, CRI rose 8.2%, and RL added 3.6%. SHOO's 1% weekly gain lagged that group, and a Wikipedia attention z-score of 7.1 as of late September points to a burst of retail interest that has not yet translated into outperformance. With the next earnings print 28 days away, the key question is whether the wholesale caution flagged by management has eased enough to justify targets that have moved meaningfully above current prices.
See the live data behind this article on ORTEX.
Open SHOO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.